Who Optimizes SG&A Costs Better? BioMarin Pharmaceutical Inc. or Pharming Group N.V.

SG&A Cost Management: BioMarin vs. Pharming

__timestampBioMarin Pharmaceutical Inc.Pharming Group N.V.
Wednesday, January 1, 20143021560004042025
Thursday, January 1, 20154022710005279557
Friday, January 1, 20164765930008073913
Sunday, January 1, 201755433600044864073
Monday, January 1, 201860435300053488904
Tuesday, January 1, 201968092400065896361
Wednesday, January 1, 202073766900069968267
Friday, January 1, 202175937500092047281
Saturday, January 1, 2022854009000131819000
Sunday, January 1, 202393730000087501000
Monday, January 1, 20241009025000
Loading chart...

Unleashing the power of data

Optimizing SG&A Costs: A Tale of Two Biopharma Giants

In the competitive world of biopharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. BioMarin Pharmaceutical Inc. and Pharming Group N.V. have taken different paths in this regard over the past decade. From 2014 to 2023, BioMarin's SG&A expenses have surged by over 200%, reflecting its aggressive expansion strategy. In contrast, Pharming Group N.V. has maintained a more conservative approach, with a modest increase of around 2,000% in the same period, albeit from a much smaller base. This stark difference highlights BioMarin's focus on scaling operations, while Pharming emphasizes cost control. As the industry evolves, these strategies will play a pivotal role in shaping their financial health and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025